TECP
VTVT icon

Trails Edge Capital Partners’s vTv Therapeutics VTVT Stock Holding History

Trails Edge Capital Partners’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.21M Sell
85,192
-54,386
-39% -$1.89M 0.51% 34
2026
Q1 		$5.54M Sell
139,578
-91,422
-40% -$3.32M 1.27% 25
2025
Q4 		$9.24M Buy
+231,000
New +$6.43M 2.28% 19

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Trails Edge Capital Partners's VTVT Position: Q2 2026 in Review

Trails Edge Capital Partners reduced its vTv Therapeutics (VTVT) stake by 39% in Q2 2026, selling an estimated $1.89M and leaving 85,192 shares worth $3.21M. The position accounts for 0.51% of the portfolio, ranked #34.

Trails Edge Capital Partners first reported a position in VTVT in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.24M in Q4 2025. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

  • Trails Edge Capital Partners held 85,192 shares of vTv Therapeutics worth $3.21M as of Q2 2026.
  • Trails Edge Capital Partners sold 54,386 vTv Therapeutics shares in Q2 2026, an estimated $1.89M.
  • vTv Therapeutics made up 0.51% of Trails Edge Capital Partners's portfolio in Q2 2026, its #34 holding.
  • Trails Edge Capital Partners first reported a position in vTv Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Trails Edge Capital Partners's vTv Therapeutics position peaked at $9.24M in Q4 2025.
  • 45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.